Data-driven Digital Design of Pharmaceutical Crystallization Processes

Mechanistic population balance modeling (PBM) has advanced the design of pharmaceutical crystallization processes, enabling the production of active pharmaceutical ingredient (API) crystals with desired critical quality attributes (CQAs), such as purity and crystal size distribution. However, PBM development can sometimes be resource-intensive, requiring extensive design of experiments (DoE) and high-quality process data, making it impractical under fast-paced industrial development timelines. This study proposes a machine learning (ML)-based workflow for developing �fit-for-purpose� digital twins of crystallization processes, leveraging industrially available DoE data to link operating conditions with CQAs. Validated on industrial data for a commercial API with complex crystallization challenges, the workflow efficiently identifies optimal operating conditions, demonstrating the potential of data-driven digital twins to accelerate the development of pharmaceutical processes.

Authors

Institutions

Publication Details

Journal
Systems and Control Transactions
Published
2025-06-30
DOI
https://doi.org/10.69997/sct.128994
Primary Topic
Crystallization and Solubility Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Data-driven Digital Design of Pharmaceutical Crystallization Processes

Charles D. Papageorgiou, Bernhard Renner, Yihui Yang, Neda Nazemifard et al.
Systems and Control Transactions
Crystallization and Solubility Studies
article

Data-driven Digital Design of Pharmaceutical Crystallization Processes

Charles D. Papageorgiou, Bernhard Renner, Yihui Yang, Neda Nazemifard, Yash Barhate, Zoltan K. Nagy, Yun-Sun Kang
article en

Abstract

Mechanistic population balance modeling (PBM) has advanced the design of pharmaceutical crystallization processes, enabling the production of active pharmaceutical ingredient (API) crystals with desired critical quality attributes (CQAs), such as purity and crystal size distribution. However, PBM development can sometimes be resource-intensive, requiring extensive design of experiments (DoE) and high-quality process data, making it impractical under fast-paced industrial development timelines. This study proposes a machine learning (ML)-based workflow for developing �fit-for-purpose� digital twins of crystallization processes, leveraging industrially available DoE data to link operating conditions with CQAs. Validated on industrial data for a commercial API with complex crystallization challenges, the workflow efficiently identifies optimal operating conditions, demonstrating the potential of data-driven digital twins to accelerate the development of pharmaceutical processes.

Systems and Control TransactionsVol. 4
Purdue University West Lafayette (US), Takeda (United States) (US)
Takeda Pharmaceuticals International
Openalex Percentile: Top 89%
Crystallization and Solubility Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Data-driven Digital Design of Pharmaceutical Crystallization Processes — Charles D. Papageorgiou, Bernhard Renner, et al. · Systems and Control Transactions (2025) | TGRS Research Map | TGRS